
SURPLUS SALE PROCEEDS OF AUSTRALIAN PROPERTIES

1. OUE Lippo Healthcare Limited (the “**Company**”) refers to its announcements dated 15 October 2020 and 8 January 2021 in relation to the receipt of the sums of A\$16,315,442.90 and A\$4,669,678.93, being the surplus sale proceeds of the three properties in Australia (553 St Kilda Road, 541 St Kilda Road, and 73-79 Little Rynie Street, Geelong, collectively the “**Australian Properties**”) from IHC Australia First Trust (Australia) and IHC Australia Second Trust (Australia) (the “**Australian Trusts**”). The Australian Trusts were previously set up by the Company to hold the Australian Properties.
2. Given that the Australian Properties had been disposed of, the Company’s Board of Directors has approved for the Company and its relevant subsidiaries to take steps to proceed with the termination of the Australian Trusts and the eventual distribution of the balance surplus sale proceeds of A\$1,214,805.11 to the Company, less payment expenses and professional fees and any outstanding liabilities of the Australian Trusts.
3. As and when there are material developments, the Company will provide further updates on the status of the above matter through SGXNet in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
20 December 2022

*This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.